Continuing metformin when starting insulin in patients with Type 2 diabetes: A double-blind randomized placebo-controlled trial

Diabetic Medicine

Volumn 22, Issue 5, 2005, Pages 634-640

  Douek, I F ^a   Allen, S E ^a   Ewings, P ^b   Gale, E A M ^a   Bingley, Polly J ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Insulin; Metformin; Therapy; Type 2 diabetes; Weight gain

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN; WELLBEING;

CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; WEIGHT GAIN;

EID: 17844366606     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01475.x     Document Type: Article

References (16)

1. UK Prospective Diabetes Study (UKPDS) Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-88.
2. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997; 278: 1663-1669.
3. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003; 326: 4-5.
4. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind placebo-controlled trial. Ann Intern Med 1999; 131: 182-188.
5. Hermann LS, Kalén J, Katzman P, Lager I, Nilsson A, Norrhamn O et al. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes Metab 2001; 3: 428-434.
6. Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, van der Burg BB et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25: 2133-2140.
7. National Institute for Clincal Excellence. Management of Type 2 Diabetes. Management of Blood Glucose. 1. London: National Institute for Clinical Excellence, 2002.
8. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999; 130: 389-396.
9. Chan NN, Brain HPS, Feher MD. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabet Med 1999; 16: 273-281.
10. The Joint Formulary Committee. Biguanides. In: Mehta DK, Martin J, eds. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2003: 312-313.
11. Bradley C. The Well-being Questionnaire. In: Bradley C, ed. Handbook of Psychology and Diabetes. Amsterdam: Harwood Academic Publishers, 1996: 89-109.
12. Bradley C. Diabetes Treatment Satisfaction Questionnaire: (DTSQ). In: Bradley C, ed. Handbook of Psychology and Diabetes. Amsterdam: Harwood Academic Publishers, 1996: 111-132.
13. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 4: 758-67.
14. Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40: 937-943.
15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
16. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18: 430-441.